Compare General Mills, Inc. (GIS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs GeneDx Holdings Corp — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: General Mills, Inc. is far larger — about 8.6× GeneDx Holdings Corp's market cap, and General Mills, Inc. pays a 7.49% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and GeneDx Holdings Corp for 19 Days on average.
| GIS | WGS | |
|---|---|---|
Market Cap | $17.43B | $2.02B |
Volume | 16,554,362 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $167.51 |
52-Week Low | $31.67 | $34.51 |
Typical Hold Time | 106 Days | 19 Days |
Enterprise Value | $30.61B | $2.05B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.29, up 1.64% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.23 and P/S of 0.96. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.797 expected, though Q4 2025 missed. The company maintains dividend payments of $0.61 per share while facing profitability challenges with negative net income margin and ROE. Leadership transition is underway with Dana McNabb set to succeed Jeff Harmening as CEO.
Outlook remains cautious with analyst consensus at Hold (61%) and $36 price target. Key risks include declining revenue trends, margin pressure, and high debt levels at 45% of assets. The stock offers value appeal but requires successful execution of the $3B savings plan and turnaround strategy to drive sustainable growth amid competitive pressures.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
